Magnetic resonance imaging and spectroscopy in evaluation of hypoxic ischemic encephalopathy in pediatric age group

Fatma Ibrahim Soliman Elshal1*, Walid Ahmed Elshehaby2, Mahmoud Abd elaziz Dawoud2 and Ekhlas Abdelmonem Shaban2

Abstract

Background: Hypoxic ischemic encephalopathy is a major cause of pediatric mortality and morbidity, with possible long-term neurologic sequel, such as cerebral palsy. With improvements in care of at-risk neonates, more children survive. This makes it increasingly important to assess, soon after birth, the prognosis of children with hypoxic ischemic encephalopathy. The aim of the study was to assess the additive role of magnetic resonance spectroscopy over conventional MRI in diagnosis and early prediction of pathological motor development in neonates with hypoxic ischemic encephalopathy.

Results: MRS ratios showed significant difference between unfavorable and normal outcome infants. MRS ratios as Lac/Cr, NAA/Cr and NAA/Cho within basal ganglia, thalamus and white matter can significantly differentiate between patients with normal and pathological outcome at 1 year.

Lac/Cr positively correlates with the severity of HIE. Both NAA/Cr and NAA/Cho negatively correlate with the severity of the disease. Ratios cutoff values as Lac/Cr above 0.38 and 0.42 in basal ganglia and white matter, respectively, NAA/Cr below 0.9 and 0.8 in basal ganglia and occipital white matter, respectively, and NAA/Cho below 0.29 and 0.31 in basal ganglia and frontal white matter, respectively, were significantly predictive of pathological outcome.

Conclusion: High Lac/Cr, low NAA/Cr and low NAA/Cho ratios within examined regions of the brain including deep grey matter nuclei as well as white matter are associated with an adverse outcome in infants with perinatal asphyxia. MRS is an accurate quantitative MR biomarker within the neonatal period for prediction of neurodevelopmental outcome after perinatal HIE. MRS may be useful in early clinical management decisions, and counseling parents thereby ensuring appropriate early intervention and rehabilitation.

Keywords: Magnetic resonance imaging, Spectroscopy, Hypoxic ischemic encephalopathy, Pediatric

Background

Perinatal asphyxia and consecutive hypoxic–ischemic encephalopathy (HIE) is a devastating condition that may lead to death or severe neurologic deficits in children such as cerebral palsy, mental retardation and epilepsy [1]. It affects more than two million newborns worldwide each year [2].

The pattern of brain injury is determined by how severe and long duration of hypoxia and degree of brain matura-
tion [1].

Investigating HIE neurodevelopmental outcomes includes clinical neurological examination, serum biomarkers, neurophysiology and neuro-imaging modalities [3].
Conventional MRI shows brain morphology at a high resolution, superior to cerebral CT and ultrasound. MRI provides essential information for diagnosing the features of HIE. Advanced neuro-imaging modalities have attained a significant role in HIE workup [4].

T1WI could provide essential information for the diagnosis and identifying typical MRI features of hypoxic–ischemic injury [5]. The imaging pattern of HIE has been classified into three types [6]; parasagittal lesions, affecting cortico-subcortical regions, profound lesions located in the basal ganglia or thalamus, and multi-cystic encephalomalacia. It has been widely reported that the potential utility of proton MR Spectroscopy could reveal brain ischemic injuries in asphyxiated neonates earlier than T1- or T2-weighted MR imaging [7]. Proton magnetic resonance spectroscopy (1H-MRS) is a quantitative, non-invasive tool used for identifying energy metabolism disturbances in the brain [8].

There is a wide range of H-MRS derived metabolites were suggested as potential biomarkers, e.g. some studies concluded that absolute Lac levels and/or Lac containing metabolite ratios (Lac/NAA, Lac/Cho, Lac/Cr) were the most accurate in prediction of outcome [9–11], while other showed that NAA/Cr, NAA/Cho, absolute NAA and/or Cho levels had promising prognostic powers [9, 10], but only few studies investigating glutamate (Glx) or glutamate-containing metabolite ratios (Glx/Cr) [2].

MRS measures concentrations of these cerebral metabolites to elucidate derangements in aerobic metabolism [7].

MRS can also detect impairment of neuronal functions which are caused by HIE. Moreover, 1H-MRS gives a good simultaneous imaging data from the cortex, basal ganglia and white matter [12].

Studies have suggested that MRS of brain metabolites may serve as a suitable tool for earlier diagnosis of HIE compared to conventional MRI and prognostication and may guide future therapies in time [8, 11, 13].

The aim of the study was to assess the additive role of magnetic resonance spectroscopy over conventional MRI in diagnosis and early prediction of pathological motor development in neonates with hypoxic–ischemic encephalopathy.

**Methods**

**Patients population**

This prospective study was carried out on 30 newly born infants, 24 full term and 6 preterm, 14 males and 16 females, their ages ranged from 6 to 60 days who clinically suspected to suffer from hypoxic–ischemic encephalopathy. The duration of this study was one year starting from November 2019 to December 2020.

Approval of Research Ethics Committee (REC) and informed consent were obtained from all guardians of patients participating in this study after explanation of the benefits and risks of the procedure. Privacy and confidentiality of all patients’ data were guaranteed. All data provision was monitored and used for scientific purpose only.

The included patients were neonates who exposed to perinatal hypoxic conditions based on history of difficult or prolonged labor, placenta previa, cord prolapse and/or severe hemorrhage. Exclusion criteria included infants of consanguineous marriage, neonates who had cardiac or brain anomalies, neonates who exposed to intrauterine infection, neonates suffered from metabolic disorders, neonates born to drug addict mother, neonates with suspected neonatal sepsis, traumatic birth injuries and kernicterus.

All the included participants were subjected to the following:

**Data collection**

- Complete history taking: all medical records of all patients were reviewed with specific attention to the perinatal history and delivery circumstances.
- Complete clinical examination: general examination was done to all patients including pulse, O2 saturation, blood pressure and temperature. All patients were classified clinically according to Sarnat and Sarnat grading system into stage I, stage II, and stage III HIE. Sarnat and Sarnat described their grading system in 1976 in a study relating electroencephalographic finding to the clinical condition of the infant and classified neonates with HIE into three stages: stage I (mild), stage II (moderate) and stage III (severe) HIE [14].
- Routine Laboratory investigations included complete blood picture, serum electrolytes (Na, K and calcium), arterial blood gases analysis and renal function test.
Fig. 1 (See legend on previous page.)
**Radiological examination**

MRI examinations were performed by using General Electric, 1.5 tesla system (signal high speed, GE medical systems).

All patients’ guardians were informed about the MRI magnets, approximate duration of MRI and MRS techniques. The examination was done during natural sleep in 6 neonates and by sedation in 24 neonates using Chloral hydrate in a dose of 50 mg/kg body weight.

All the patients were examined in a supine position with use of a standard head coil and immobilized in a comfortable position.

All neonates were studied with a 1.5-T whole body MR imager equipped with high-performance gradients, using a manufacturer supplied quadrant head coil.

**Routine sequences performed in all participants** Magnetic resonance imaging (MRI) including Sagittal T2-weighted (300/14/1[TR/TE/excitations]), Axial fast spin echo T2-weighted (3000/91/1), Axial fast fluid attenuation inversion recovery (FLAIR) (10002/172/1, T1 2.2s), Axial T1-weighted (500/14/1) and diffusion-weighted images (DWI) was performed with an axial single shot echoplanar spin-echo sequence (TR/TE: 10000/89.9–99.3).

In general, all axial sequences used 5 mm thickness with intersection gap of 2.5 mm, a 256 × 192 matrix, the same imaging angle along orbitomeatal line and a 22 or 24 cm field of view.

In magnetic resonance spectroscopy (MRS), Axial FLAIR imaging was used for voxels localization. Grid measured 16 × 16 was applied; only 8 separate voxels were individual placed in four regions of interest at both sides; the frontal and parieto-occipital white matter, thalamus and basal ganglia bilaterally. A voxel size of 1.5 × 1.5 × 1.5 cm³ to 2 × 2 × 2 cm³ was used. Contact with the cerebrospinal fluid and skull bone was avoided.

Frontal voxels encompassed cortex medially at the level of the anterior interhemispheric fissure, and voxels placed within parieto-occipital subcortical white matter encompassed cortex of the medial occipital lobe and parietal lobe. Typical acquisition time was 5 min 4 s per spectral acquisition 20 min for all.

Localization tool was used which is known as spectroscopic imaging (MRSI) or chemical shift imaging (CSI); this method overcomes the poorer quality due to the greater magnetic field inhomogeneities that occur over the larger volume in (MVS).

Localized shimming, phase correction, water suppression calibration and scan acquisition to eliminate artifacts caused by eddy currents were performed prior to acquisition of the spectra.

The pulse sequence used was point resolved spectroscopy (PRESS) with parameters; long TE (TR/TE = 2000/144 ms) and short TE (TR/TE = 2000/35 ms).

Long TE was used to clearly visualize intensity peak of NAA, Cho and Cr and to calculate NAA/Cr, NAA/Cho and Cho/Cr ratios. Short TE was mainly used to illustrate Lac peak and to calculate Lac/Cr ratio.

Data were post-processed at GE Advantage workstation provided by the magnitude spectra processed automatically by baseline correction and curve-fitting procedures to determine the resonance areas of various metabolites.

Image interpretation: reporting MRI and MRS images were done by two conjoined neuro-radiologists with inter observer agreement (MD, 35 years of experience and ES, 15 years of experience) blinded to clinical data.

**Patients’ follow up**

Sensorineural and psychomotor integrity of patients was assessed clinically by using Bayley Scales of Infant and Toddler Development, 3rd edition (Bayley III scale) [15].

**Statistical analysis**

Statistical analysis and presentation of data were conducted using SPSS version 22 computer program. All numerical variables were checked for normality by Shapiro–Wilk test. Normally distributed numerical variables were presented as mean ± SD, and differences between two groups were tested using independent T-test, whereas differences between three groups were analyzed by the one-way ANOVA test. When results of ANOVA were significant, post hoc Games–Howell test was performed for pairwise comparison of each two groups. Categorical variables were summarized as frequencies and percentages, and association between variables was tested using X2 tests (Pearson’s Chi-square for independence or Fisher Exact Tests as appropriate). Furthermore, Receiver operating characteristics (ROC) curve analysis was carried out to test the discrimination power of the studied ratios to predict the outcomes. Areas under the

(See figure on next page.)

**Fig. 2** A 20-days-old female patient weighted 2750 gm presented clinically by respiratory distress-Sarnat stage II. Conventional MRI Axial T1WI (A, B) shows rim of high signal intensities (germinal matrix hemorrhage) in the left occipital horn and adjacent to the frontal horn of lateral ventricle (red arrows). Axial T2WI (C) shows dilatation of the ventricular system (black arrow) and dilatation of subarachnoid spaces (central and peripheral atrophic changes) (blue arrows), indistinct grey white matter differentiation (green arrows). Multivoxel MRS (D) and MRS Spectrum (E) long TE 144 show decreased NAA peak, and increased CHO peak also Multivoxel MRS (F) and spectrum (G) short TE 35 show marked increased lac peak. Lac/Cr at basal ganglia & thalamus ratio 2.7 denoting marked stage of HIE (grade III). Outcome: Cerebral palsy
Fig. 2 (See legend on previous page.)
were delivered vaginally. neonates 60% were born by caesarian section and 40% group ranging from 2 to < 3 kg. Among the examined There were 53.4% of the examined neonates in the weight average weight was 2250–4400 g (mean, 3243 ± 0.49, 0.83 ± 0.42, 2.79 ± 0.33 in stages I, II, and III, respectively. The difference in Lac/Cr ratio between three stages of HIE was statistically significant (P ≤ 0.001). Also stage III had significantly higher Lac/Cr ratio than stages I and II (P = 0.002, < 0.001 and < 0.001).

NAA/Cr in basal ganglia in HIE stages I, II and III were 1.06 ± 0.01, 0.84 ± 0.10, and 0.56 ± 0.04, respectively. The difference in NAA/Cr ratio between three stages of HIE was statistically significant (P ≤ 0.001). Also stage III had significantly lower NAA/Cr ratio than HIE stages I and II (P ≤ 0.001, < 0.001 and < 0.001).

NAA/Cr in frontal white matter in HIE stages I, II and III were 1.10 ± 0.02, 0.83 ± 0.17, and 0.57 ± 0.04, respectively. The difference in NAA/Cr ratio between three stages of HIE was statistically significant (P ≤ 0.001). Also stage III had significantly lower NAA/Cr ratio than HIE stages I and II (P ≤ 0.001, < 0.001 and < 0.001).

NAA/Cho in basal ganglia in HIE stages I, II and III were 0.39 ± 0.02, 0.3 ± 0.05 and 0.17 ± 0.03. The difference in NAA/Cho ratio between three stages of HIE was statistically significant (P ≤ 0.001). Also stage III had significantly lower NAA/Cho ratio than HIE stages I and II (P ≤ 0.001, < 0.001 and < 0.001).

NAA/Cho in frontal white matter in HIE stages I, II and III were 0.41 ± 0.01, 0.31 ± 0.04 and 0.18 ± 0.03. The difference in NAA/Cho ratio between three stages of HIE was statistically significant (P ≤ 0.001). Also stage III had significantly lower NAA/Cho ratio than HIE stages I and II (P ≤ 0.001, < 0.001 and < 0.001).

Cho/ Cr in basal ganglia, thalamus, frontal and occipital white matter was statistically insignificant in differentiating between the three stages of HIE.

Each of Lac/Cr, NAA/Cr within basal ganglia, frontal and occipital white matter were significant in differentiating neonates with normal and poor outcomes at 1 year (P ≤ 0.001 and < 0.001).

Although normal neonatal MRS usually reveals mildly elevated choline and reduced NAA due to incomplete myelination process, yet significant difference was also noted regarding NAA/choline ratio within frontal and occipital white matter, basal ganglia between infants who had poor outcome, and those with normal outcome (P = 0.001).

Cho/Cr ratio within basal ganglia and white matter was statistically insignificant in differentiating between neonates with normal and poor outcomes. As regarding (Tables 3, 4). ROC curve analysis revealed that Lac/Cr ratio higher than 0.38, 0.36, 0.42 in basal ganglia, thalamus and white
matter can significantly differentiate cases with poor outcome as regard.
NAA/Cr ratio lower than 0.9, 0.75, 0.9, 0.8 in basal ganglia, thalamus, frontal and occipital NAA/Cho ratio lower than 0.29, 0.25, 0.31, 0.3 in basal ganglia, thalamus, frontal and occipital white matter can significantly differentiate cases with poor outcome (Table 5).

Discussion
Perinatal hypoxia is a vital cause of long-term neurologic complications ranging from mild behavioral deficits to intractable seizures, mental retardation, and cerebral palsy. With improvements in care of at-risk neonates, more and more children survive. This makes it increasingly important to assess, soon after birth, the prognosis of children with hypoxic–ischemic encephalopathy [16]. Magnetic resonance imaging (MRI) is a leading source of brain injury biomarkers in perinatal HIE. Different patterns of brain injury by conventional MRI have been related to severity and phenotype of neurodevelopmental sequel after HIE. However, conventional MRI requires availability of an experienced pediatric neuroradiologist, can be subjective, and provides broad severity classification on an ordinal scale [17]. Quantitative MRI techniques such as MRS can

Table 1 MRI findings in the studied patients

| MRI finding                  | No | %    |
|-----------------------------|----|------|
| Normal                      | 16 | 53.3%|
| Periventricular leukomalacia | 4  | 13.3%|
| Germinal matrix hemorrhage  | 2  | 6.7% |
| Ventriculomegaly            | 4  | 13.3%|
| White matter injury         | 4  | 13.3%|
| Intracerebral hematoma      | 4  | 13.3%|
| Reduced myelination         | 6  | 20%  |
| Brain edema                 | 5  | 16.7%|

Table 2 Relation between MRS grading and patients’ outcome

| Grading                | I  | II | III |
|------------------------|----|----|-----|
| Death                  | 0  | 0  | 2   |
| Cerebral palsy         | 0  | 2  | 10  |
| Developmental delay    | 0  | 4  | 2   |
| Normal                 | 10 | 0  | 0   |

Table 3 Comparison of the studied ratios at various studied sites according to Sarnat staging

| HIE staging | F     | P value | P1   | P2   | P3   |
|-------------|-------|---------|------|------|------|
| Basal ganglia |       |         |      |      |      |
| lac/Cr ratio | Mean ± SD | 0.19 ± 0.02 | 0.83 ± 0.42 | 2.79 ± 0.33 | 406.87 | < 0.001* | 0.003* | < 0.001* | < 0.001* |
| NAA/Cr ratio | Mean ± SD | 1.06 ± 0.01 | 0.84 ± 0.10 | 0.56 ± 0.04 | 975.09 | < 0.001* | < 0.001* | < 0.001* | < 0.001* |
| NAA/Cho ratio | Mean ± SD | 0.39 ± 0.02 | 0.3 ± 0.05 | 0.17 ± 0.03 | 159.43 | < 0.001* | < 0.001* | < 0.001* | < 0.001* |
| Cho/Cr ratio | Mean ± SD | 2.92 ± 0.34 | 2.94 ± 0.23 | 3.15 ± 0.26 | 2.77  | 0.101 | Not applicable |
| Thalamus |       |         |      |      |      |
| lac/Cr ratio | Mean ± SD | 0.2 ± 0.04 | 0.92 ± 0.49 | 3.04 ± 0.50 | 223.76 | < 0.001* | < 0.001* | < 0.001* | < 0.001* |
| NAA/Cr ratio | Mean ± SD | 1.07 ± 0.01 | 0.84 ± 0.11 | 0.56 ± 0.05 | 640.92 | < 0.001* | < 0.001* | < 0.001* | < 0.001* |
| NAA/Cho ratio | Mean ± SD | 0.4 ± 0.01 | 0.28 ± 0.03 | 0.18 ± 0.02 | 351.74 | < 0.001* | < 0.001* | < 0.001* | < 0.001* |
| Cho/Cr ratio | Mean ± SD | 2.88 ± 0.31 | 2.91 ± 0.23 | 3.15 ± 0.26 | 3.34  | 0.068 | Not applicable |
| Frontal WM |       |         |      |      |      |
| lac/Cr ratio | Mean ± SD | 0.18 ± 0.03 | 0.97 ± 0.49 | 2.94 ± 0.38 | 358.51 | < 0.001* | 0.002* | < 0.001* | < 0.001* |
| NAA/Cr ratio | Mean ± SD | 1.10 ± 0.02 | 0.83 ± 0.17 | 0.57 ± 0.04 | 765.59 | < 0.001* | 0.002* | < 0.001* | < 0.001* |
| NAA/Cho ratio | Mean ± SD | 0.41 ± 0.01 | 0.31 ± 0.04 | 0.18 ± 0.03 | 228.16 | < 0.001* | < 0.001* | < 0.001* | < 0.001* |
| Cho/Cr ratio | Mean ± SD | 2.87 ± 0.30 | 2.91 ± 0.22 | 3.08 ± 0.17 | 2.92  | 0.095 | Not applicable |
| Occipital WM |       |         |      |      |      |
| lac/Cr ratio | Mean ± SD | 0.25 ± 0.09 | 0.9 ± 0.49 | 3.09 ± 0.45 | 249.05 | < 0.001* | 0.005* | < 0.001* | < 0.001* |
| NAA/Cr ratio | Mean ± SD | 1.11 ± 0.02 | 0.82 ± 0.09 | 0.46 ± 0.01 | 287.11 | < 0.001* | < 0.001* | < 0.001* | < 0.001* |
| NAA/Cho ratio | Mean ± SD | 0.4 ± 0.02 | 0.31 ± 0.02 | 0.17 ± 0.03 | 184.80 | < 0.001* | < 0.001* | < 0.001* | < 0.001* |
| Cho/Cr ratio | Mean ± SD | 3.03 ± 0.29 | 3.04 ± 0.20 | 3.15 ± 0.26 | 858   | 0.447 | Not applicable |

* Significant at p < 0.05
Table 4 Comparison between patients with favorable and unfavorable outcomes regarding the studied ratios at the various studied sites

| Outcome | Favorable N=10 | Unfavorable N=20 | T | P value |
|---------|----------------|-----------------|---|---------|
| Basal ganglia | | | | |
| Lac/Cr ratio | Mean±SD | 0.26±0.9 | 2.29±8.2 | 10.96 | <0.001* |
| NAA/Cr ratio | Mean±SD | 1.02±0.7 | 0.62±11 | 10.92 | <0.001* |
| NAA/CHO ratio | Mean±SD | 0.37±0.3 | 0.2±0.5 | 9.64 | <0.001* |
| CHO/Cr ratio | Mean±SD | 2.9±3 | 3.09±25 | 1.82 | 0.079 |
| Thalamus | | | | |
| Lac/Cr ratio | Mean±SD | 0.26±0.8 | 2.5±92 | 7.64 | <0.001* |
| NAA/Cr ratio | Mean±SD | 1.03±0.6 | 0.62±10 | 13.56 | <0.001* |
| NAA/CHO ratio | Mean±SD | 0.35±0.6 | 0.21±0.5 | 7.26 | <0.001* |
| CHO/Cr ratio | Mean±SD | 2.9±28 | 3.07±27 | 1.45 | 0.158 |
| Frontal WM | | | | |
| Lac/Cr ratio | Mean±SD | 0.27±12 | 2.47±82 | 11.75 | <0.001* |
| NAA/Cr ratio | Mean±SD | 1.07±0.4 | 0.61±07 | 19.08 | <0.001* |
| NAA/CHO ratio | Mean±SD | 0.39±0.4 | 0.21±0.6 | 8.54 | <0.001* |
| CHO/Cr ratio | Mean±SD | 2.9±28 | 3.02±20 | 1.41 | 0.169 |
| Occipital WM | | | | |
| Lac/Cr ratio | Mean±SD | 0.29±0.8 | 2.54±93 | 10.80 | <0.001* |
| NAA/Cr ratio | Mean±SD | 1.04±09 | 0.55±14 | 10.0 | <0.001* |
| NAA/CHO ratio | Mean±SD | 0.37±0.4 | 0.21±0.6 | 9.25 | <0.001* |
| CHO/Cr ratio | Mean±SD | 3.05±26 | 3.10±24 | 0.509 | 0.615 |

*Significant at p < 0.05

overcome these limitations by providing continuous, reproducible measures of brain microstructural and metabolic injury [7].

MRS outperforms MRI in detecting abnormalities of metabolism even when normal structures are present on magnetic resonance (MR) imaging studies. Therefore, combination of MR studies and 1 HMRS may make it possible to evaluate severity and help predicting outcome of HIE [18].

MRI examination was normal in nearly half of the patients (16 cases) (all had lac peak on MRS examination), the remaining 14 cases showed multiple abnormalities as periventricular leukomalacia (PVL) and ventriculomegaly, reduced myelination (absent of high signal intensity of PLIC in T1WI), white matter injury displaying hypo intensity signal in T1WI and hyper intensity in T2WI, germinal matrix hemorrhage, brain atrophy, and smudged grey white matter differentiation (brain edema). These findings are in agreement with Zhu et al. [19] who examined 31 neonates with HIE classified in 3 groups underwent follow-up MRI. All patients in group I died. In group II (moderate HIE), the abnormalities observed in the brains of patients included extensive extracerebral spaces and encephalatrophy, cerebral infarction, focal encephalomalacia and encephalatrophy, multiple cyst-like encephalomalacia, marble-like basal ganglia, periventricular leukomalacia, myelin hypoevolutism, gliosis, and thinning of corpus callosum. In group III, normal or slightly extensive extracerebral spaces were observed. For 11 cases in group III, MRI detected slightly extensive extracerebral spaces in 2 cases. The MRI examination was normal in 9 cases. Also in the study of Guo et al. [4] out of the total of 29 cases, 13 cases had no MRI abnormalities; 10 had minor to moderate abnormalities; 4 cases had severe abnormalities; with two mortality cases (one after 6 days and one after 12 days).

Patients were classified by MRS into 3 groups according to the value of Lac/Cr ratio; Group I had Lac/Cr lower than 0.5, Group II in which Lac/Cr ranging between 0.5 and 1.5 and Group III in which Lac/Cr ratio was higher than 1.5.

It was found that Lac/Cr ratio positively correlates with clinical staging, severity of brain abnormalities in MRI examination and patients’ outcome on neurological examination at 1 year so it promotes worse prognosis. As in group III with the highest Lac/Cr ratio which included 14 patients all from stage III Sarnat, highest incidence of brain abnormalities on MRI examination and the worst prognosis (2 cases died, 10 cases developed cerebral palsy and 2 cases had delayed development), in group II which included 6 patients all from Sarnat II stage showing normal MRI examination, 4 cases had developmental delay and 2 cases had cerebral palsy, but in group I included 10 patients (6 patients were clinically classified as Sarnat stage I and 4 patients as Sarnat stage II) all of them had normal neurological examination on follow-up.

These results are in agreement with the Egyptian study Noaman et al. [20] who studied the role of MRS and chemical biomarkers in grading and assessing the severity and prognosis of HIE non-invasively in 30 newborn with HIE (15 stage I Sarnat, 11 stage II Sarnat, 4 stage III Sarnat) and concluded that Lac/Cr was a good indicator in recognition of the outcome as in the group whom Lac/Cr greater than 1.5 severe clinical symptoms and signs (Sarnat stage III) were present and then all neonates were died.
These results also match with Fan et al. [18] who studied MRI and MR spectroscopy in 38 full-term neonates suffered from HIE (9 neonates with Sarnat stage I, 13 Sarnat stage II and 16 stage III according to clinical signs and the presence of a history of asphyxia) and illustrated that the group whose Lac/Cr ratio more than 1.5 had severe lesions detected by MRI and poor outcome and they concluded that MRS is a very useful tool in diagnosing patients with HIE and predicting their outcome.

In 1HMRS peak metabolites ratios: At the level of basal ganglia, Lac/Cr and NAA/Cho ratios had higher sensitivity 95 than NAA/Cr 90 while highest specificity was for Lac/Cr 90.1 versus NAA/Cr 90 then NAA/Cho 87. At the level of thalamus, each of Lac/Cr, NAA/Cr and NAA/Cho ratios had equal sensitivity 80, while Lac/Cr ratio had higher specificity 100 versus NAA/Cr 92 then NAA/Cho 89. At the level of frontal white matter, NAA/Cr and NAA/Cho showed higher sensitivity 95 than Lac/Cr while Lac/Cr and NAA/Cho showed higher specificity 80 than NAA/Cr 70. At the level of occipital white matter NAA/Cho was the highest sensitivity 95 versus NAA/ Cr and Lac/Cr 90 and 87 while Lac/Cr was the highest specificity 100 versus NAA/Cr and NAA/Cho 80 and 75, respectively. Lac/Cr ratio higher than 0.38, 0.36, 0.42 in basal ganglia, thalamus and white matter was significantly predictive of pathological outcome. NAA/Cr ratio lower than 0.9, 0.75, 0.9, 0.8 in basal ganglia, thalamus, frontal and occipital white matter was significantly predictive of pathological outcome. The current study found that NAA/Cr and NAA/Cho were significantly lower in patients with poor outcome than patients with favorable outcome. This is in agreement with Lally et al. [21] who examined 223 neonates of whom 160 examined by MRS in a multi-centric cohort study to assess the diagnostic accuracy of MRS biomarkers as early predictors of neurodevelopmental abnormalities observed years after neonatal encephalopathy and found that each of NAA/Cr, NAA/Cho, Lac/NAA and NAA concentration are specific and sensitive in predicting patient’s outcome. Cutoff value of NAA/Cho within the thalamus was < 0.22 (close to found in current result 0.25) showing significant correlation with poor outcome.

These results also are in consistent with Ancora et al. [7] who studied 20 full-term neonates with different stages of perinatal hypoxia and found that MR spectroscopy is an accurate early predictor for poor neurologic outcome in neonates as the difference of NAA/Cr, NAA/ Cho and Lac/NAA between normal neonates and others with pathological outcome was statistically significant. NAA/Cr ratio ≤0.67 within the basal ganglia (close to study’s cutoff 0.75 in thalamus and 0.9 within basal ganglia) was significant of poor outcome.

There is disagreement with Guo et al. [4] who examined 24 neonates and found that MRS is a useful technique for distinguishing between HIE and normal newborns. However, with regard to differentiating between grades, MRS should be interpreted in conjunction with performances on T1WI in reverse to current study in which the differences of Lac/Cr, NAA/Cr and NAA/Cho ratios between mild, moderate and severe cases were statistically significant (P=0.05). Also the ascent in Lac/Cr ratio was not marked in contrast to present study. It seems likely that this difference of results is related to the time of the MRS examination with respect to the hypoxic–ischemic event. The mean time from injury to MRS in patients in the

| Cutoff | Sensitivity % (95% CI) | Specificity % (95% CI) | AUC | 95% CI of AUC | P value |
|--------|------------------------|------------------------|-----|--------------|---------|
| Lac/Cr ratio in BG | >0.38 | 95 (75.1–99.9) | 90 (55.5–99.7) | 0.93 | 0.74–0.98 | <0.001* |
| Lac/Cr ratio in thalamus | >0.36 | 80 (56.3–94.3) | 100 (69.2–100) | 0.94 | 0.78–0.99 | <0.001* |
| Lac/Cr ratio in frontal WM | >0.42 | 85 (62.1–96.8) | 80 (44.4–97.5) | 0.91 | 0.77–0.99 | <0.001* |
| Lac/Cr ratio occipital WM | >0.42 | 87 (62.5–97) | 100 (69.2–100) | 0.93 | 0.76–0.99 | <0.001* |
| NAA/Cr ratio in BG | ≤0.9 | 90 (68.3–98.8) | 90 (55.5–99.7) | 0.91 | 0.75–0.98 | <0.001* |
| NAA/Cr ratio in thalamus | ≤0.75 | 80 (56.5–94.5) | 92 (95.5–99.7) | 0.93 | 0.78–0.99 | <0.001* |
| NAA/Cr ratio in frontal WM | ≤0.9 | 95 (75.1–99.9) | 70 (34.8–93.3) | 0.90 | 0.74–0.98 | <0.001* |
| NAA/Cr ratio in occipital WM | ≤0.8 | 90 (68.3–98.8) | 80 (44.4–97.5) | 0.82 | 0.64–0.93 | <0.001* |
| NAA/Cho ratio in BG | ≤0.29 | 95 (75.3–99.5) | 87 (44.4–99.5) | 0.78 | 0.59–0.91 | <0.001* |
| NAA/Cho ratio in thalamus | ≤0.25 | 80 (56.3–94.3) | 89 (45.5–99.9) | 0.86 | 0.69–0.96 | <0.001* |
| NAA/Cho ratio in frontal WM | ≤0.31 | 95 (75.1–99.9) | 80 (44.4–97.5) | 0.80 | 0.61–0.92 | <0.001* |
| NAA/Cho ratio in occipital WM | ≤0.30 | 95 (75.1–99.9) | 75 (54.4–98.5) | 0.79 | 0.59–0.91 | <0.001* |

*Significant at p < 0.05

Table 5  Diagnostic performance of the studied ratios for the outcome of patients by ROC curve analysis
current study was 23 days; for patients in Guo et al. [4] was 7 days.

The present results proved that in all examined regions HIE stage III had significantly higher Lac/Cr ratio than stage II than stage I. This matches Thayyil et al. [11] who reviewed all studies that compared MR biomarkers performed during the neonatal period (including conventional MRI, DWI and MRS) with neurodevelopmental outcome at age of 1 year and found that MRS specifically Lac/NAA and Lac/Cr ratio had better diagnostic accuracy than conventional MRI performed at any time during the neonatal period.

On the other hand, a larger recent study was done by Alderliesten et al. [8] who studied 88 neonates, 22 of whom died and 7 had unfavorable motor outcome. They documented that infants with poor outcome had obviously higher Lac/NAA ratios than infants with a normal outcome. This current study has relied on Lac/Cr ratio in adverse to many studies which depended on Lac/NAA ratio as it is an unreliable index of Lac accumulation as NAA is often reduced in hypoxic–ischemic injury as mentioned by Cady [22].

At the level of parieto-occipital cortex and basal ganglia Ancora et al. [9] had examined 23 patients with mean age from 7 to 10 days and concluded that NAA/Cr and Lac/Cr measured at parietal–occipital level were the best predictors of outcome. Cutoff value of Lac/Cr > 0.3 (close to current study > 0.42) at parietal-occipital level was able to discriminate between newborns that developed CP and those that did not until 2 years of age. Similar to this recent study which found that Lac/Cr ratio was significantly higher in patients with poor outcome than patients with favorable outcome and that NAA/Cr ratio was significantly lower in patients with poor outcome than patients with favorable outcome.

Other studies match current results as Shanmugalingam et al. [23] who studied 21 newborns with HIE and documented that compared with normal outcome, lactate/Cr and lactate/NAA were higher and NAA/Cr was lower in patients who had severe outcome and Cheong et al. [24] who studied the value of MRS in the thalamus in 17 newly born infants suffered from perinatal HIE and also concluded that Lac/Cho, Lac/Cr and Lac/NAA in neonates with neonatal encephalopathy with severe outcome were all increased compared with control values and with those infants with normal or mild outcome. In addition, NAA/Cr and NAA/Cho in the severe outcome group were reduced compared with both control and normal or mild groups.

It was found that in all examined regions HIE stage III had significantly higher Lac/Cr ratio and lower NAA/Cr and NAA/Cho ratios than stage II than stage I. This is in agreement with Zhu et al. [19] who examined 46 patients to investigate the prognostic values of MRS obtained from neonatal brains with hypoxic–ischemic encephalopathy and found that, Glx-a/Cr and Lac/Cr values were higher in the moderate and severe HIE groups than in the mild HIE group, whereas the NAA/Cho and NAA/Cr values in severe HIE group were much lower than in mild and moderate HIE. Additionally, there was positive correlation between the values of Glx-a/Cr and Lac/Cr and the severity of brain injury. But there was a negative correlation between the values of NAA/Cr and NAA/Cho and the severity of brain injury in HIE (in current study glutamine was not measured by MRS machine).

The results in the present study were also consistent with those of the study of Barkovich et al. [25] in which patients experienced injury within an average of 7 days prior to MRS and found associations with NAA levels in HIE and a preliminary study of Cady [22] in which metabolite concentrations in neonates with neonatal encephalopathy documented increases in (Lac) and reductions in (NAA), (Cho), and (Cr) similar to those reported in this current study.

Limitation

For ethical reasons, there was no control group. Another limitation of this study is common to nearly all studies of neonatal encephalopathy, that precise time of injury was not known in most of the patients. The extent and pattern of injury vary temporally. Some areas will appear more severely injured and some less injured, depending on the timing of the scan with respect to the injury.

Conclusion

MRS in addition to MRI elevates the degree of confidence in diagnosis of HIE patients especially in mild and moderate cases, so it is recommended to be added to MRI examination.

High Lac/Cr, low NAA/Cr and low NAA/Cho ratios within examined regions of the brain including deep grey matter nuclei as well as white matter are associated with an adverse outcome in infants with perinatal asphyxia. MRS is an accurate quantitative MR biomarker within the neonatal period for prediction of neurodevelopmental outcome after perinatal HIE. MRS may be useful in early clinical management decisions, and counseling parents thereby ensuring appropriate early intervention and rehabilitation.
Abbreviations
MRI: Magnetic resonance imaging; MRS: Magnetic resonance spectroscopy; Lac: Lactate; Cr: Creatine; NAA: N-acetyl aspartate; Cho: Choline; GLX: Glutamate; HE: Hypoxic ischemic encephalopathy; T1WI: T1-weighted images; T2WI: T2-weighted images; DWI: Diffusion-weighted images; FLAIR: Fluid attenuation inversion recovery; PVL: Periventricular leukomalacia; PLIC: Posterior Limb of Internal Capsule; ROC: Receiver operating characteristics; PRESS: Point resolved spectroscopy; MVS: Multiple voxel spectroscopy; CSI: Chemical shift imaging; MRSI: Magnetic resonance spectroscopic imaging.

Acknowledgements
To all the participants for their cooperation and patience.

Authors’ contributions
ES suggested the research idea, ensured the original figures and data in the work, minimized the obstacles to the team of work, correlated the study concept and design and had the major role in analysis, MD supervised the study with significant contribution to design the methodology, manuscript revision and preparation. WE correlated the clinical data of patient and matched it with the findings, drafted and revised the work. FE collected data in all stages of manuscript, performed data analysis. All authors read and approved the final manuscript for submission.

Funding
No funding. Not applicable for this section.

Availability of data and materials
The authors confirm that all data supporting the finding of the study are available within the article and the raw data and data supporting the findings were generated and available to the corresponding author on request.

Declarations

Ethics approval and consent to participate
Written informed consent was obtained from all patients’ guardians after full explanation of the benefits and risks of procedure, the study was approved by ethical committee of Tanta university hospital, faculty of medicine (32187/03/18).

Consent for publication
All participants included in the research gave written consent to publish the data included in the study. Authors accepted to publish the paper.

Competing interests
The authors declare that they have no competing of interests.

Author details
1 Radiology Department, Faculty of Medicine, Tanta University, El-geish street, Tanta, Gharbeya governorate, Egypt. 2 Faculty of Medicine, Tanta University, El-geish street, Tanta, Gharbeya governorate, Egypt.

Received: 9 May 2021 Accepted: 30 July 2021
Published online: 10 August 2021

References
1. Bano S, Chaudhary V, Garga UC (2017) Neonatal hypoxic-ischemic encephalopathy: a radiological review. J Pediatr Neurosci 12:1–6
2. Barta H, Jermendy A, Kolossvary M et al (2018) Prognostic value of early, conventional proton magnetic resonance spectroscopy in cooled asphyxiated infants. BMC Pediatr 18:302–313
3. Zou R, Xiong T, Zhang L et al (2018) Proton magnetic resonance spectroscopy biomarkers in neonates with hypoxic-ischemic encephalopathy: a systematic review and meta-analysis. Front Neurol 9:732–745
4. Guo L, Wang D, Bo G et al (2016) Early identification of hypoxic-ischemic encephalopathy by combination of magnetic resonance (MR) imaging and proton MR spectroscopy. Exp Ther Med 12:2835–2842
5. Jadas V, Brassaeu-Daudry M, Chollat C et al (2013) The contribution of the clinical examination, electroencephalogram, and brain MRI in assessing the prognosis in term newborns with neonatal encephalopathy. A cohort of 30 newborns before the introduction of treatment with hypothermia. Arch Peditr 21:125–133
6. Gano D, Dauvilliers Y, Poskitt KJ et al (2013) Evolution of pattern of injury and quantitative MR on days 1 and 3 in term newborns with hypoxic–ischemic encephalopathy. Pediatr Res 74:82–87
7. Ancora G, Testa C, Grandi S et al (2013) Prognostic value of brain proton MR spectroscopy and diffusion tensor imaging in newborns with hypoxic–ischemic encephalopathy treated by brain cooling. Neuroradiology 55(8):1017–1025
8. Alderliesten T, de Vries LS, Staats L et al (2017) MRI and spectroscopy in (near) term neonates with perinatal asphyxia and therapeutic hypothermia. Arch Dis Child Fetal Neonatal Ed 102(2):147–152
9. Ancora G, Soffritti S, Locci R et al (2010) A combined a-EEG and MR spectroscopy study in term newborns with hypoxic–ischemic encephalopathy. Brain Dev 32:835–842
10. Van Doormaal PJ, Meiners LC, Ter Horst HJ et al (2012) The prognostic value of multivoxel magnetic resonance spectroscopy determined metabolite levels in white and grey matter brain tissue for adverse outcome in term newborns following perinatal asphyxia. Eur Radiol 22:772–778
11. Thayyil S, Chandrasekaran M, Taylor A et al (2010) Cerebral magnetic resonance biomarkers in neonatal encephalopathy: a meta-analysis. Pediatrics 125(2):382–395
12. Mansour Y, Hanfy O, Fathy S, Mohammed E (2017) Magnetic resonance imaging versus proton magnetic resonance spectroscopy in neonatal hypoxic ischemic encephalopathy in Egyptian population: pilot study. J Neurol Neurosurg Psychiatry 88:43–50
13. Alderliesten T, De Vries LS, Benders MJ et al (2011) MR imaging and outcome of term neonates with perinatal asphyxia: value of diffusion-weighted MR imaging and 1 H MR spectroscopy. Radiology 261:235–242
14. Sarnat HB, Sarnat MS (1978) Neonatal encephalopathy following fetal distress: a clinical and electroencephalographic study. Arch Neurol 36:636–705
15. Yu Y, Hsieh S, Hsu H, Chen C, Lee T, Chu C, Jeng F (2013) A psychometric study of the Bayley Scales of Infant and Toddler Development–3rd Edition for term and preterm Taiwanese infants. Res Dev Disabil 34(11):3875–3883
16. Doppelf F, Maypole J, Sinha B, Currier H, DeBasso W, Augustyn M (2014) “More than meets the eye”: when the neonatal course may impact several years out. J Dev Behav Pediatr 35(7):467–469
17. Agut T, Leon M, Rebollo M, Muchart J, Arca G, Garcia-Altix A (2014) Early identification of brain injury in infants with hypoxic ischemic encephalopathy at high risk for severe impairments: accuracy of MR performed in the first days of life. BMC Pediatr 14:177
18. Fan G, Wu Z, Chen L et al (2003) Hypoxia-ischemic encephalopathy in full-term neonate: correlation proton MR spectroscopy with MR imaging. Eur J Radiol 45(2):91–98
19. Zhu W, Zhong W, Jianpin Q et al (2008) Proton magnetic resonance spectroscopy in neonates with hypoxic-ischemic injury and its prognostic value. Transl Res 152(5):225–233
20. Noaman A, Elshafey A, Al-Shahawy A et al (2013) MR spectroscopy, S100B protein and NSE analysis as early predictors of hypoxic ischaemic encephalopathy. Egypt J Radiol Nucl Med 44(2):309–320
21. Lally PJ, Montaldo P, Oliveira V et al (2019) Magnetic resonance spectroscopy study in term newborns with hypoxic–ischemic encephalopathy. Arch Dis Child Fetal Neonatal Ed 102(2):147–152
22. Cady EB (1996) Metabolite concentrations and relaxation in perinatal encephalopathy. J Neurol Neurosurg Psychiatry 60(3):187–191
23. Shanmugalingam S, Thornton JS, Iwata O et al (2006) Comparative prognostic utilities of early quantitative magnetic resonance imaging spin-spin relaxometry and proton magnetic resonance spectroscopy in neonatal encephalopathy. Pediatrics 118(4):1467–1477
24. Cheong JL, Cady EB, Penrice J et al (2006) Proton MR spectroscopy in neonates with perinatal cerebral hypoxic-ischemic injury: metabolite peak-area ratios, relaxation times, and absolute concentrations. AJNR Am J Neuroradiol 27(7):1546–1554
25. Barkovich AJ, Miller SP, Bartha A et al (2006) MR imaging, MR spectroscopy, and diffusion tensor imaging of sequential studies in neonates with encephalopathy. Am J Neuroradiol 27(3):533–547

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.